



Australian Government
Department of Health
Therapeutic Goods Administration

Record Summary table with fields: Record Summary (227282), 98 Alive Immune, Sponsor (98 Alive Pty Ltd), Therapeutic Type (Medicine), Product Category (Listed), ARTG Start date (26/08/2014), Postal Address, Billing Address.

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.
The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine.
The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.
The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.
All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports.
The sponsor shall not supply the listed medicine after the expiry date of the goods.
Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Manufacturers

Table with 3 columns: Name, Address, Manufacturing steps. The table content is mostly redacted with a large black box.

Record Summary

Products

1.98 Alive Immune

Product Type Single Medicine Product **Status** Current
Effective date 26/08/2014

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Supports a healthy immune system
 Antioxidant

Warnings

ZINC WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

No Warnings included on Record

Specific Conditions

Components

1.

Dosage form Capsule, hard
Route of Administration Oral
Maximum daily dose 2
Weight of divided preparation 720 mg

Formulations

Active Ingredients	Category	Quantity	Units
Melaleuca alternifolia	AHN	150	mg
Plant details (origin)	Part	Preparation	
	leaf	Oil essential	
Equivalent			
Melaleuca Oil		145.2	mg
cineole		3.6	microgram
Cajuput Oil		0	microgram
zinc amino acid chelate	AAN	75	mg
Equivalent			
zinc		15	mg

Excipient Ingredients	Category	Quantity	Units
Empty Gelatin Capsules Size 00 White Op White Op (PI 12969)	PI		
microcrystalline cellulose	AAN		
silicon dioxide	AAN		